The American Journal of Managed Care highlights the latest research from Erika Hamilton

Sarah Cannon Research Institute shared the following post on LinkedIn:

“AJMC – The American Journal of Managed Care highlights the latest research from SCRI expert, Erika Hamilton, MD, on advancements in antibody-drug conjugates (ADCs) and their potential in oncology. Read about the new targets and sequencing questions in this article.”

Erika Hamilton reshared this post, adding the following:

“Thanks to AJMC – The American Journal of Managed Care highlighting our ADC session at ASCO24.

From lung to breast to myeloma, across tumor types ADCs are coming and regardless of tumor type we share future directions of:
1) figuring out ideal targets and payloads,
2) sequencing,
3) mechanisms of resistance,
4) recognition of unique side effects from drug to drug.”

Source: Sarah Cannon Research Institute/LinkedIn and Erika Hamilton/LinkedIn
.
Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective.

Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference, and a board member of the Susan G. Komen Foundation of Central Tennessee.